| | 基础化工 | 江西省 | | --- | --- | --- | | | | 上海市 | | 环境违法违规 | 建筑装饰 | 四川省 | | | | 北京市 | | | 农林牧渔 | 海南市 | | | 环保 | 江苏省 | 每经AI快讯，"A股绿色报告"项目监控到的数据显示，四川双马（000935）间接控股子公司湖北健翔生 物制药有限公司多肽药物扩建项目环评审批获原则同意。该项目总投资额达5亿元。该审批信息于2026 年1月6日被相关监管机构披露。 "A股绿色报告"项目由每日经济新闻联合环保领域知名NGO公众环境研究中心（IPE）共同推出，旨在 让上市公司环境信息更加阳光透明。本项目基于31个省（区、市）、337个地级市政府发布的权威环境 监管数据，筛选监控上市公司及其旗下公司（包括分公司、参股公司和控股公司）的环境表现，加以专 业数据分析及深入解读，每日智能写作及时发布上市公司AI绿报，每周推出A股绿色周报，定期动态更 新上市公司环境风险榜。 上期（总第229期）A股绿色周报显示，共有6家上市公司在近期暴露了环境风险。 (记者 刘志远 陈俊杰) 免责声明：本文内容与数据仅供参考，不构成投资建议，使 ...

Core Insights - Artificial intelligence (AI) is accelerating drug development globally, highlighting the increasing interdependence between China and the U.S. in this field [1] - The competitive advantage in AI-driven drug development relies not only on computational power but also on the ability to efficiently extract data from genomics and clinical trials, with China emerging as a significant data source for the U.S. [1][3] Group 1: AI in Drug Development - The first step in building effective AI models for drug development is data collection, which involves integrating dispersed data from various countries [3] - U.S. pharmaceutical companies heavily rely on Chinese clinical data to support their AI model training and drug development processes [3] - China's clinical trial ecosystem is considered one of the best globally, characterized by a large patient base and rapid recruitment speeds [3] Group 2: Market Dynamics and Collaborations - In 2025, Chinese pharmaceutical companies completed 157 early drug licensing agreements totaling $135.7 billion, primarily with large Western pharmaceutical firms [4] - Notable collaborations include a $5.6 billion exclusive licensing agreement between Rongchang Biologics and AbbVie for a new PD-1/VEGF dual-target antibody drug [4] - Chinese biotech firms are leveraging partnerships with multinational companies to access international markets, as seen in the collaboration between Takeda Pharmaceutical and Innovent Biologics, valued at $11.4 billion [4] Group 3: Challenges and Future Outlook - Despite advancements, U.S. remains a leader in AI-driven drug development due to superior AI technology and a mature venture capital ecosystem [5] - The U.S. is tightening control over biological data, with recent legislation seen as a strategic move to limit collaboration with Chinese biotech firms [5] - The global pharmaceutical industry is transitioning from traditional drug discovery methods to AI-supported automated laboratories capable of conducting thousands of experiments daily [5] Group 4: Growth Projections for AI in Pharmaceuticals - The global AI pharmaceutical market is projected to reach $5.62 billion by 2028, with long-term estimates ranging from $28 billion to $53 billion [6] - In China, the AI pharmaceutical sector is expected to experience rapid growth, with market size anticipated to exceed 500 billion RMB by 2025-2030, maintaining a compound annual growth rate of over 15% [6]

Core Viewpoint - The research team from East China University of Science and Technology has developed a non-natural oxidase toolbox for the selective oxidation of taxanes, which lays a solid foundation for the efficient synthesis of paclitaxel and its analogs [2][4]. Summary by Sections Research Development - The study published in Nature Communications focuses on designing an oxidase toolbox that enables site-directed oxidation at multiple positions (C-4, C-6, C-10, C-11, C-12, and C-13) of the taxane skeleton, resulting in the efficient synthesis of 11 new taxane structures [2][4]. - The research addresses the bottleneck in the biosynthesis of paclitaxel, which has been hindered by the low catalytic efficiency and poor expression of natural P450 enzymes responsible for multi-site oxidation [4][5]. Methodology - The team screened 29 types of fungal peroxidases and found that the non-specific peroxygenase TteUPO from Thielavia terrestris exhibited the highest oxidation activity towards taxadiene [4][5]. - The crystal structure of TteUPO was analyzed, leading to the redesign of the enzyme's substrate channel, which improved catalytic efficiency and expanded oxidation sites [5]. Outcomes - A toolbox containing seven key mutants was constructed, allowing for high regio- and stereoselective oxidation at six different sites on the taxane skeleton [5]. - This toolbox not only shows excellent catalytic performance for taxadiene but also for various higher oxidation state taxane derivatives, providing a rich set of enzymatic tools for the green biosynthesis of complex natural products like paclitaxel [5].

Core Viewpoint - The company, Xiansheng Zaiming Pharmaceutical Co., Ltd., has submitted an IPO application to the Hong Kong Stock Exchange, aiming to establish a dedicated financing platform for its oncology business, which is currently under the parent company, Xiansheng Pharmaceutical [1][8]. Financial Performance - The company reported revenues of 1.522 billion yuan, 1.296 billion yuan, and 1.238 billion yuan for the years 2023, 2024, and the first nine months of 2025, respectively [2]. - Despite stable revenue growth, the company remains in a loss position due to high R&D and sales expenses, recording net losses of 336 million yuan, 506 million yuan, and 303 million yuan for the same periods [6]. - R&D costs were 831 million yuan, 708 million yuan, and 512 million yuan for 2023, 2024, and the first nine months of 2025, with R&D expenses exceeding 50% of revenue in 2023 and 2024 [5]. Business Strategy - The company focuses on the development and commercialization of innovative oncology drugs, having five commercialized products that contribute over 90% of total revenue [4]. - The split from Xiansheng Pharmaceutical allows the company to optimize its financial structure while maintaining absolute control over the oncology business [2]. - The company has established a sales and marketing team of over 1,200 people to enhance product marketization [5]. Market Position and Collaborations - Xiansheng Zaiming has engaged in multiple licensing collaborations with companies like AbbVie, Ipsen, and NextCure, with a potential total transaction value exceeding 2.8 billion USD [5]. - The company ranks first in the number of oncology asset transactions and fourth in total value among Chinese biopharmaceutical companies [5]. Challenges and Considerations - The company faces challenges related to high market channel concentration, with the top five customers accounting for over 65% of revenue [11]. - The overall gross margin has decreased from approximately 72% to 68.1%, attributed to structural adjustments in revenue sources and product mix [12]. - The company has set a timeline for its IPO process, needing to submit its application by June 2027 and complete the listing by the end of 2028, with penalties for delays [12].

Group 1 - The core focus of the Hong Kong IPO market since 2026 has been on the pharmaceutical industry, particularly innovative drugs, with several companies seeking to list on the Hong Kong Stock Exchange [1] - Exegenesis Bio Inc. (嘉因生物) has submitted its application to the Hong Kong Stock Exchange, aiming to list under Chapter 18A, with CCB International as its sole sponsor [1] - The company has raised a total of 940 million RMB in multiple financing rounds since its establishment in May 2019, with a post-investment valuation of approximately 5.78 billion USD (around 40 billion RMB) as of June 2021 [4] Group 2 - Exegenesis Bio focuses on gene therapy and oligonucleotide drugs, having developed a dual technology platform consisting of AAVarta and SODA, which are crucial for gene delivery and regulation [9][10] - The company has several product pipelines, including EXG001-307 for treating spinal muscular atrophy (SMA) type 1, and EXG102-031 and EXG202 for age-related macular degeneration (wAMD) and other eye diseases [12][22] - The global market for SMA drug treatments is projected to grow from 4.64 billion USD in 2024 to 5.93 billion USD by 2030, with a compound annual growth rate of 4.2% [16] Group 3 - Exegenesis Bio reported a loss of 314 million RMB during the reporting period, with cash and cash equivalents amounting to 262 million RMB as of September 30, 2025 [23][27] - The company has not yet achieved profitability since its inception, with losses of 220 million RMB and 94.33 million RMB recorded in 2024 and the first nine months of 2025, respectively [25][26] - The company faces significant competition in the gene therapy sector, with multiple international pharmaceutical giants also developing treatments for SMA and wAMD [24][29]

东方创新医疗股票A（018045）成立日期2023年5月8日，最新规模1070.2万。今年以来收益8.85%，同 类排名1479/5542；近一年收益34.05%，同类排名2266/4235；成立以来收益8.43%。 东方创新医疗股票A（018045）基金经理为蔡尚军。 截至发稿，蔡尚军累计任职时间1年335天，现任基金资产总规模5488.34万元，任职期间最佳基金回报 10.94%， 任职期间最差基金回报1.41%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 1月20日，迈威生物跌5%，截至发稿，报39.88元/股，成交2.72亿元，换手率3.28%，总市值159.36亿 元。 资料显示，迈威(上海)生物科技股份有限公司位于中国(上海)自由贸易试验区蔡伦路230号2幢105室香港 铜锣湾希慎道33号利园1期19楼1928室，成立日期2017年5月12日，上市日期2022年1月18日，公司主营 业务涉及治疗用生物制品的研发、生产与销售。主营业务收入构成为：销售商品9 ...

Core Viewpoint - The company clarified that the share changes by directors and executives in January 2026 are not due to secondary market sell-offs, but rather a repurchase and cancellation operation in accordance with the "2023 Restricted Stock Incentive Plan" [1] Group 1 - The company responded to investor inquiries on its interactive platform regarding share changes [1] - The repurchase and cancellation of shares are part of the implementation of the "2023 Restricted Stock Incentive Plan" [1] - The details of the share repurchase and cancellation were disclosed in the announcement dated January 10, 2026, with the announcement number 2026-002 [1]

Core Viewpoint - Insilico Medicine has entered into a strategic partnership with Shenzhen Hengtai Biotechnology to jointly develop ISM8969, a novel oral NLRP3 inhibitor aimed at treating central nervous system diseases [1] Group 1: Partnership Details - The collaboration will accelerate the global development of ISM8969 [1] - Insilico Medicine grants Hengtai Biotechnology 50% rights for research, development, registration, production, and commercialization of ISM8969 worldwide [1] Group 2: Financial Terms - Insilico Medicine is set to receive over HKD 500 million in upfront and milestone payments [1] - An upfront payment of HKD 78 million is expected to be paid within 30 days of the agreement's effective date [1]

Group 1 - The core viewpoint of the article highlights the significant developments in the Chinese pharmaceutical industry, particularly in the context of AI applications and innovation in drug development [1] - The AI healthcare sector is experiencing intense competition, with applications in healthcare accounting for 43% of the total AI usage globally, indicating a pivotal moment for AI in the medical field [1] - By 2025, the National Medical Products Administration (NMPA) in China is expected to approve 76 innovative drugs, surpassing the U.S. FDA for the first time, with total licensing transactions for innovative drugs exceeding $130 billion [1] Group 2 - The ChiNext Medical ETF (159377) tracks the Innovation Medicine Index (399275), which focuses on innovative pharmaceutical sectors, selecting companies with high R&D investment and innovation capabilities [2] - The index aims to reflect the overall performance of leading companies in the pharmaceutical industry that possess both growth potential and technological attributes [2] - The daily price fluctuation limit for the index is set at 20%, indicating a high level of volatility and potential for significant price movements [2]

Core Viewpoint - The stock of Zymeworks Inc. (02617) has experienced a decline of over 10%, currently trading at 84.7 HKD, with a transaction volume of 117 million HKD [1] Group 1: Stock Performance - Zymeworks Inc. shares fell by 9.02% to 84.7 HKD as of the latest report [1] - The stock has seen a significant drop following the announcement of a new share placement [1] Group 2: Share Placement Announcement - The company plans to place 21 million new shares at a price of 92.85 HKD per share, representing a discount of 17.98% compared to the closing price of 113.2 HKD on January 13 [1] - The net proceeds from the placement are expected to be 190 million HKD [1] Group 3: Use of Proceeds - Approximately 60% of the funds will be allocated to clinical trials for the core product Tinengotinib in treating cholangiocarcinoma (CCA) and other indications [1] - About 30% of the proceeds will be used for the development of other products, including TT-00973, TT-01488, and other molecules [1] - The remaining 10% will be utilized for working capital and general corporate purposes [1]